NVAX
Novavax, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.22
−1.16%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 40.54x
- P/S forward
- 8.43x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -8.84x
- Price / sales
- 4.07x
- Price / cash flow
- -42.68x
Enterprise value
- Enterprise value
- $1.3B
- EV / sales
- 3.05x
- EV / EBITDA
- -6.23x
- EV / EBIT
- -5.55x
- Market cap
- $1.7B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026